Side-by-side comparison of AI visibility scores, market position, and capabilities
Closed $80M Series D (Apr 2026). FDA-cleared IND for ER-100 in optic neuropathies (Jan 2026). Phase 1 enrolling. Co-founded by Harvard's David Sinclair.
Life Biosciences is running the first FDA-cleared human trial of partial epigenetic reprogramming, using gene therapy to reverse vision loss caused by aging. Co-founded by Harvard aging biologist David Sinclair — whose research showed that aged retinal cells could be restored to youthful function by expressing Yamanaka factors — Life Biosciences received FDA clearance for its IND (Investigational New Drug) for ER-100 in optic neuropathies in January 2026 and closed an $80 million Series D in April 2026.
Adept AI raised $415M to pioneer computer-use AI agents; its core research and agent team moved to Amazon in 2024 in a landmark talent acquisition while the company continues developing ACT-1 for enterprise automation.
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and executing multi-step workflows in any application. Its ACT-1 model demonstrated the ability to control web browsers and desktop applications through natural language instructions, pioneering the computer-use agent paradigm that Anthropic later commercialized with Claude's computer use feature.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.